Resource icon

Safety, Tolerability and Efficacy for CGF166 in Patients With Bilateral Hearing Loss

The goal of the current study is to evaluate the safety, tolerability, and the potential ability of CGF166 delivered through IL-infusion to improve hearing and vestibular function. CGF166 is a recombinant adenovirus 5 (Ad5) vector containing a cDNA encoding the human Atonal transcription factor (Hath1).

Estimated Enrollment: 45
Study Start Date: June 2014
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Author
Tinnitus Talk
Views
36
First release
Last update
Rating
0.00 star(s) 0 ratings

More resources from Tinnitus Talk